An Uncontrolled, Open-label Phase IIb Trial of Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Sponsors Bayer
- 12 Sep 2017 Planned End Date changed from 31 Jul 2017 to 10 Nov 2017.
- 16 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 2 May 2017.
- 16 Mar 2017 Status changed from recruiting to active, no longer recruiting.